Focus on sarcomas

Cancer Cell

Volumn 2, Issue 3, 2002, Pages 175-178

  Mackall, Crystal L ^a   Meltzer, Paul S ^b   Helman, Lee J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA;

CLEAR CELL SARCOMA; DESMOPLASTIC SMALL ROUND CELL TUMOR; DISEASE ASSOCIATION; EWING SARCOMA; FAMILIAL CANCER; GASTROINTESTINAL STROMAL TUMOR; GENETIC ANALYSIS; HISTIOCYTOMA; HUMAN; IONIZING RADIATION; MYXOSARCOMA; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; RETINOBLASTOMA; REVIEW; RHABDOMYOSARCOMA; RISK FACTOR; SARCOMA; SYNOVIAL SARCOMA; CELL DIFFERENTIATION; GENE TRANSLOCATION; GENETICS;

CELL DIFFERENTIATION; HUMANS; SARCOMA; TRANSLOCATION, GENETIC;

EID: 0036728833     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(02)00132-0     Document Type: Review

References (30)

1. Abramson, D.H., Ellsworth, R.M., Kitchin, F.D., and Tung, G. (1984). Second nonocular tumors in retinoblastoma survivors. Are they radiation-induced? Ophthalmology 91, 1351-1355.
2. Allander, S.V., Nupponen, N.N., Ringner, M., Hosteller, G., Maher, G.W., Goldberger, N., Chen, Y., Carpten, J., Elkahloun, A.G., and Meltzer, P.S. (2001). Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile. Cancer Res. 61, 8624-8628.
3. Arndt, C.A., and Crist, W.M. (1999). Common musculoskeletal tumors of childhood and adolescence. N. Engl. J. Med. 341, 342-352.
4. Arvand, A., and Denny, C.T. (2001). Biology of EWS/ETS fusions in Ewing's family tumors. Oncogene 20, 5747-5754.
5. Ashkenazi, A., Pai, R.C., Fong, S., Leung, S., Lawrence, D.A., Marsters, S.A., Blackie, C., Chang, L., McMurtrey, A.E., Hebert, A., et al. (1999). Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104, 155-162.
6. Bennicelli, J.L., and Barr, F.G. (2002). Chromosomal translocations and sarcomas. Curr. Opin. Oncol. 14, 412-419.
7. Berman, J., and O'Leary, T.J. (2001). Gastrointestinal stromal tumor workshop. Hum. Pathol. 32, 578-582.
8. Bramwell, V., Rouesse, J., Steward, W., Santoro, A., Schraffordt-Koops, H., Buesa, J., Ruka, W., Priario, J., Wagener, T., Burgers, M., et al. (1994). Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma-reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J. Clin. Oncol. 12, 1137-1149.
9. Dash, A.B., Williams, I.R., Kutok, J.L., Tomasson, M.H., Anastasiadou, E., Lindahl, K., Li, S., Van Etten, R.A., Borrow, J., Housman, D., et al. (2002). A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. Proc. Natl. Acad. Sci. USA 99, 7622-7627.
10. Dematteo, R.P., Heinrich, M.C., El-Rifai, W.M., and Demetri, G. (2002). Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum. Pathol. 33, 466-477.
11. Deneen, B., and Denny, C.T. (2001). Loss of p16 pathways stabilizes EWS/FLI1 expression and complements EWS/FLI1 mediated transformation. Oncogene 20, 6731-6741.
12. Evdokiou, A., Bouralexis, S., Atkins, G.J., Chai, F., Hay, S., Clayer, M., and Findlay, D.M. (2002). Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. Int. J. Cancer 99, 491-504.
13. Heinrich, M.C., Blanke, C.D., Druker, B.J., and Corless, C.L. (2002). Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J. Clin. Oncol. 20, 1692-1703.
14. Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T., Ishiguro, S., Kawano, K., Hanada, M., Kurata, A., Takeda, M., et al. (1998). Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279, 577-580.
15. Kelly, L.M., Kutok, J.L., Williams, I.R., Boulton, C.L., Amaral, S.M., Curley, D.P., Ley, T.J., and Gilliland, D.G. (2002). PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proc. Natl. Acad. Sci. USA 99, 8283-8288.
16. Khan, J., Bittner, M.L., Saal, L.H., Teichmann, U., Azorsa, D.O., Gooden, G.C., Pavan, W.J., Trent, J.M., and Meltzer, P.S. (1999). cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proc. Natl. Acad. Sci. USA 96, 13264-13269.
17. Khan, J., Wei, J.S., Ringner, M., Saal, L.H., Ladanyi, M., Westermann, F., Berthold, F., Schwab, M., Antonescu, C.R., Peterson, C., and Meltzer, P.S. (2001). Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat. Med. 7, 673-679.
18. King, A.A., Debaun, M.R., Riccardi, V.M., and Gutmann, D.H. (2000). Malignant peripheral nerve sheath tumors in neurofibromatosis 1. Am. J. Med. Genet. 93, 388-392.
19. Kontny, H.U., Hammerle, K., Klein, R., Shayan, P., Mackall, C.L., and Niemeyer, C.M. (2001). Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis. Cell Death Differ. 8, 506-514.
20. Landuzzi, L., De Giovanni, C., Nicoletti, G., Rossi, I., Ricci, C., Astolfi, A., Scopece, L., Scotlandi, K., Serra, M., Bagnara, G.P., et al. (2000). The metastatic ability of Ewing's sarcoma cells is modulated by stem cell factor and by its receptor c-kit. Am. J. Pathol. 157, 2123-2131.
21. Lejeune, F.J., Pujol, N., Lienard, D., Mosimann, F., Raffoul, W., Genton, A., Guillou, L., Landry, M., Chassot, P.G., Chiolero, R., et al. (2000). Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. Eur. J. Surg. Oncol. 26, 669-678.
22. Li, F.P., and Fraumeni, J.F., Jr. (1969). Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J. Natl. Cancer Inst. 43, 1365-1373.
23. Malkin, D., Li, F.P., Strong, L.C., Fraumeni, J.F., Jr., Nelson, C.E., Kim, D.H., Kassel, J., Gryka, M.A., Bischoff, F.Z., Tainsky, M.A., et al. (1990). Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250, 1233-1238.
24. Nishida, T., Hirota, S., Taniguchi, M., Hashimoto, K., Isozaki, K., Nakamura, H., Kanakura, Y., Tanaka, T., Takabayashi, A., Matsuda, H., and Kitamura, Y. (1998). Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat. Genet. 19, 323-324.
25. Petak, I., Douglas, L., Tillman, D.M., Vernes, R., and Houghton, J.A. (2000). Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis. Clin. Cancer Res. 6, 4119-4127.
26. Rubin, B.P., Singer, S., Tsao, C., Duensing, A., Lux, M.L., Ruiz, R., Hibbard, M.K., Chen, C.J., Xiao, S., Tuveson, D.A., et al. (2001). KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 61, 8118-8121.
27. Schoenmakers, E.F., Wanschura, S., Mois, R., Bullerdiek, J., Van den Berghe, H., and Van de Ven, W.J. (1995). Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours. Nat. Genet. 10, 436-444.
28. Singer, S., Demetri, G.D., Baldini, E.H., and Fletcher, C.D. (2000). Management of soft-tissue sarcomas: an overview and update. Lancet Oncol. 1, 75-85.
29. Tuveson, D.A., Willis, N.A., Jacks, T., Griffin, J.D., Singer, S., Fletcher, C.D., Fletcher, J.A., and Demetri, G.D. (2001). STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 20, 5054-5058.
30. van Oosterom, A.T., Judson, I., Verweij, J., Stroobants, S., Donato di Paola, E., Dimitrijevic, S., Martens, M., Webb, A., Sciot, R., Van Glabbeke, M., et al. (2001). Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358, 1421-1423.